Given that human IL-6 and vIL-6 (as well as IL-10) signal through gp130 and the JAK/STAT pathway and that STAT3 has been shown to be toxic to PEL cells in vitro18,22,23, we decided to explore JAK inhibitors as possible therapy for PEL and KSHV-MCD. The gene discussed is STAT3; the disease is primary effusion lymphoma.